Evidence map›Paper›PMID 39745975›Full record

ArticleScience (New York, N.Y.)2025

Rare germline structural variants increase risk for pediatric solid tumors.

Riaz Gillani, Ryan L Collins, Jett Crowdis, Amanda Garza, Jill K Jones, Mark Walker, Alba Sanchis-Juan, Christopher W Whelan, Emma Pierce-Hoffman, Michael E Talkowski and 8 more

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Germline determinants of risk and molecular subtype in young-onset lung cancer.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. SMARCAL1 is a new osteosarcoma predisposition gene.Journal of the National Cancer Institute · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Riaz Gillani *Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-8643-2725
Ryan L Collins *Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-1268-9995
Jett CrowdisHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-4777-7303
Amanda GarzaCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8557-8765
Jill K JonesHarvard Medical School, Boston, MA, USA.ORCID 0000-0001-8837-1807
Mark WalkerData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-6613-4560
Alba Sanchis-JuanCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-2885-4692
Christopher W WhelanData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8446-8468
Emma Pierce-HoffmanData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michael E TalkowskiHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-2889-0992
Harrison BrandHarvard Medical School, Boston, MA, USA.
Kevin HaigisCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jaclyn LoPiccoloCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-0043-0206
Saud H AlDubayanCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alexander GusevCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7980-4620
Brian D CromptonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine A JanewayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6000-3594
Eliezer M Van AllenCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0201-4444

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Research Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9M
Scalable tool and comprehensive maps to interpret structural variation across the neuropsychiatric spectrumR01MH115957 · NIMH · BROAD INSTITUTE, INC. · PI TALKOWSKI, MICHAEL E · 2019 to 2025
$5.4M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatmentK08CA276701 · NCI · DANA-FARBER CANCER INST · PI Riaz Gillani · 2023 to 2026
$788k
Dissecting the Role of Germline Genetics in RAS-Driven CancersK99CA286805 · NCI · DANA-FARBER CANCER INST · PI COLLINS, RYAN LEWIS · 2024 to 2025
$327k
NCI NIH HHS K08 CA276701NCI NIH HHS K99 CA286805NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA222574NCI NIH HHS T32 CA136432NCI NIH HHS U01 CA233100NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196173NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273NIMH NIH HHS R01 MH115957
6 · The paper itself

Abstract

Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using germline genome sequencing of 1765 affected children, their 943 unaffected parents, and 6665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we uncovered burdens of ultrarare SVs that cause loss of function of highly expressed, mutationally constrained genes, as well as noncoding SVs predicted to disrupt chromatin domain boundaries. Collectively, we estimate that rare germline SVs explain 1.1 to 5.6% of pediatric cancer liability, establishing them as an important component of disease predisposition.

Indexed as

Bone NeoplasmsGenetic Predisposition to DiseaseGenomic Structural VariationGerm-Line MutationNeuroblastomaSarcoma, EwingAdultChildChild, PreschoolChromatinChromosome AberrationsFemaleHumansLoss of Function MutationMaleRisk FactorsChromatin

Identifiers

PMID39745975
PMCPMC12873715

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.